Full Text View
Tabular View
No Study Results Posted
Related Studies
Alemtuzumab and CHOP in T-cell Lymphoma (ACT-1)
This study is currently recruiting participants.
Study NCT00646854   Information provided by University of Aarhus
First Received: February 14, 2008   Last Updated: September 29, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, T-Cell, Peripheral
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Additional drug interventions recognized in this trial
Alemtuzumab
Cyclophosphamide
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Aarhus University Hospital
GCP-unit at Aarhus University Hospital, Aarhus, Denmark


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services